{"pmid":32303756,"title":"Impact of anti-tnfalpha antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases.","text":["Impact of anti-tnfalpha antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases.","J Crohns Colitis","Tursi, Antonio","Papa, Alfredo","32303756"],"journal":"J Crohns Colitis","authors":["Tursi, Antonio","Papa, Alfredo"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303756","week":"202016|Apr 13 - Apr 19","doi":"10.1093/ecco-jcc/jjaa076","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1664431720521269250,"score":8.233237,"similar":[{"pmid":32215548,"title":"Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","text":["Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.","J Crohns Colitis","Monteleone, Giovanni","Ardizzone, Sandro","32215548"],"abstract":["Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia."],"journal":"J Crohns Colitis","authors":["Monteleone, Giovanni","Ardizzone, Sandro"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215548","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa061","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352134975881216,"score":89.48516},{"pmid":32246874,"title":"Management of Inflammatory Bowel Diseases in the Wake of COVID-19 Pandemic.","text":["Management of Inflammatory Bowel Diseases in the Wake of COVID-19 Pandemic.","J Gastroenterol Hepatol","Pasha, Syed Bilal","Fatima, Huda","Ghouri, Yezaz A","32246874"],"journal":"J Gastroenterol Hepatol","authors":["Pasha, Syed Bilal","Fatima, Huda","Ghouri, Yezaz A"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246874","week":"202014|Mar 30 - Apr 05","doi":"10.1111/jgh.15056","source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1663352135864025088,"score":80.84915},{"pmid":32303607,"title":"British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.","text":["British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.","The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.","Gut","Kennedy, Nicholas A","Jones, Gareth-Rhys","Lamb, Christopher A","Appleby, Richard","Arnott, Ian","Beattie, R Mark","Bloom, Stuart","Brooks, Alenka J","Cooney, Rachel","Dart, Robin J","Edwards, Cathryn","Fraser, Aileen","Gaya, Daniel R","Ghosh, Subrata","Greveson, Kay","Hansen, Richard","Hart, Ailsa","Hawthorne, A Barney","Hayee, Bu'Hussain","Limdi, Jimmy K","Murray, Charles D","Parkes, Gareth C","Parkes, Miles","Patel, Kamal","Pollok, Richard C","Powell, Nick","Probert, Chris S","Raine, Tim","Sebastian, Shaji","Selinger, Christian","Smith, Philip J","Stansfield, Catherine","Younge, Lisa","Lindsay, James O","Irving, Peter M","Lees, Charlie W","32303607"],"abstract":["The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials."],"journal":"Gut","authors":["Kennedy, Nicholas A","Jones, Gareth-Rhys","Lamb, Christopher A","Appleby, Richard","Arnott, Ian","Beattie, R Mark","Bloom, Stuart","Brooks, Alenka J","Cooney, Rachel","Dart, Robin J","Edwards, Cathryn","Fraser, Aileen","Gaya, Daniel R","Ghosh, Subrata","Greveson, Kay","Hansen, Richard","Hart, Ailsa","Hawthorne, A Barney","Hayee, Bu'Hussain","Limdi, Jimmy K","Murray, Charles D","Parkes, Gareth C","Parkes, Miles","Patel, Kamal","Pollok, Richard C","Powell, Nick","Probert, Chris S","Raine, Tim","Sebastian, Shaji","Selinger, Christian","Smith, Philip J","Stansfield, Catherine","Younge, Lisa","Lindsay, James O","Irving, Peter M","Lees, Charlie W"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303607","week":"202016|Apr 13 - Apr 19","doi":"10.1136/gutjnl-2020-321244","keywords":["crohn's colitis","crohn's disease","ulcerative colitis"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["China","Italy","GBR","GBR","British"],"countries":["Italy","United Kingdom","China"],"countries_codes":["ITA|Italy","GBR|United Kingdom","CHN|China"],"_version_":1664431720487714818,"score":72.03929},{"pmid":32276846,"title":"Challenges in paediatric inflammatory bowel diseases in the COVID-19 time.","text":["Challenges in paediatric inflammatory bowel diseases in the COVID-19 time.","Dig Liver Dis","Dipasquale, Valeria","Cucchiara, Salvatore","Martinelli, Massimo","Miele, Erasmo","Aloi, Marina","Romano, Claudio","32276846"],"journal":"Dig Liver Dis","authors":["Dipasquale, Valeria","Cucchiara, Salvatore","Martinelli, Massimo","Miele, Erasmo","Aloi, Marina","Romano, Claudio"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32276846","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.dld.2020.03.015","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663798882974302208,"score":70.55575},{"pmid":32282624,"title":"Telemedicine for Pediatric Inflammatory bowel disease in the Era of COVID-19.","text":["Telemedicine for Pediatric Inflammatory bowel disease in the Era of COVID-19.","J Pediatr Gastroenterol Nutr","Verstraete, Sofia G","Sola, Ana Marija","Ali, Sabina A","32282624"],"journal":"J Pediatr Gastroenterol Nutr","authors":["Verstraete, Sofia G","Sola, Ana Marija","Ali, Sabina A"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282624","week":"202016|Apr 13 - Apr 19","doi":"10.1097/MPG.0000000000002747","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664182200827904000,"score":70.55575}]}